Clinical Trial Results


Topical Ruxolitinib Evaluation in Vitiligo Study 1 (TRuE-V1)

Topical Ruxolitinib Evaluation in Vitiligo Study 2 (TRuE-V2) 

See May 17, 2021 Press Release 


This is an implanted drug that works by stimulating melanocytes to generate pigment, or melanin. Although clinical trials have been completed, this medicine is not yet accessible on the market. Please see the link below for further information on this trial.

 JAK Inhibitors 

This class of medication blocks the JAK pathway, which is responsible for T cells migrating to the skin and destroying melanocytes. There are currently two published case reports where these medications induced repigmentation in patients with vitiligo. However, no large clinical trials have been performed and this medication is currently not covered by insurance. For more information on the published case reports, please click the links below:


Steroids reduce the amount of T cells in the body and have anti-inflammatory actions. These are the cells that destroy the pigment-producing cells, known as melanocytes. Oral steroids are frequently used to assist prevent disease progression and are administered either as pulse dose (a few days a week) or as regular dosing. They’re frequently used in conjunction with other therapies, such as light therapy. Please see the following websites for more information on the usage of oral steroids in vitiligo:

Join Our Vitiligo Community

Are you dealing with a recent diagnosis or know someone who has vitiligo? We’re here to help you figure out what works best to manage symptoms and improve overall day-to-day life whether you or someone you love is affected.

Stay up-to-date on the latest news about treatments and managing symptoms. Sign up to get important email updates with relevant information.

This field is for validation purposes and should be left unchanged.